Merck (NYSE: MRK) reported Q2 EPS of $1.87, $0.19 better than the analyst estimate of $1.68. Revenue for the quarter came in at $14.6 billion versus the consensus estimate of $13.83 billion.

GUIDANCE:

Merck sees FY2022 EPS of $7.25-$7.35, versus the consensus of $7.36. Merck sees FY2022 revenue of $57.5-58.5 billion, versus the consensus of $58.1 billion.

For earnings history and earnings-related data on Merck (MRK) click here.